ZIVO Bioscience (OTCMKTS:ZIVO) Shares Pass Above Fifty Day Moving Average of $2.98

Shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVOGet Rating) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.98 and traded as high as $3.47. ZIVO Bioscience shares last traded at $3.28, with a volume of 6,484 shares traded.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reduced their price target on ZIVO Bioscience from $9.00 to $6.00 in a research report on Monday, February 13th.

ZIVO Bioscience Trading Down 0.8 %

The stock has a 50-day simple moving average of $2.98 and a 200-day simple moving average of $3.10. The company has a market cap of $30.90 million, a price-to-earnings ratio of -3.31 and a beta of 0.19.

Institutional Trading of ZIVO Bioscience

An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. lifted its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVOGet Rating) by 19.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 92,468 shares of the biotechnology company’s stock after buying an additional 15,147 shares during the period. Vanguard Group Inc. owned approximately 0.98% of ZIVO Bioscience worth $359,000 at the end of the most recent reporting period. 5.05% of the stock is currently owned by institutional investors.

ZIVO Bioscience Company Profile

(Get Rating)

Zivo Bioscience, Inc engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.

See Also

Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.